Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

BACKGROUND: The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical eff...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Santini, Daniele, Vincenzi, Bruno, Schiavon, Gaia, La Cesa, Annalisa, Gasparro, Simona, Vincenzi, Angelo, Tonini, Giuseppe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2006
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1402306/
https://ncbi.nlm.nih.gov/pubmed/16504126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-42
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller